GC Genome Corporation (KOSDAQ:340450)

Market Cap	156.57B
Revenue (ttm)	31.53B +21.8%
Net Income	4.04B
EPS	184.57
Shares Out	23.65M
PE Ratio	35.87
Forward PE	28.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	126,803
Average Volume	288,291
Open	6,740.00
Previous Close	6,620.00
Day's Range	6,740.00 - 7,090.00
52-Week Range	6,200.00 - 15,180.00
Beta	n/a
RSI	37.15
Earnings Date	Apr 10, 2026

About GC Genome

GC Genome Corporation operates as a clinical genome analysis company in South Korea. It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names; Guardant360, a blood genetic profiling test; Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test; and genetic rare disease testing services for chromosomal microarray, targeted exome sequencing, whole exome sequencing, and diagnostic genome sequencing. The compan...

• Industry: Medical - Equipment & Services
• Sector: Healthcare
• Founded: 2013
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 340450